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Abstract
Introduction: Apart from the well-studied mechanisms of disease course modification, many therapeutic interventions, at least
in part, exert non-specific effects on patients. These effects can be measured by patient self-assessment or by technical
analyses. The aim of the study was to assess the extent of placebo effect in the treatment of asthma based on revaluation of
results of high-quality trials on inhaled antiasthmatic drugs and in the context of various applied investigative methods.
Material and methods: A systematic search of the Medline database (using the Entrez Pubmed browser) was performed
using international drug names and English terms: inhaled, randomised, placebo-controlled. The aim of the search was to
identify trials on the efficacy of inhaled antiasthmatic drugs. Of the returned 454 studies, 41 were further included in
metaanalysis and assessed for correlations between drug effects and respective applied investigative methods. For com-
parison, analogical analysis was performed for captopril, with 232 identified published studies of which 10 were included in
the metaanalysis.
Results: The placebo effect in the treatment of asthma was significantly stronger (29%) as compared to the placebo effect of
captopril in patients treated for arterial hypertension (17%). The placebo effect was more prominent in studies applying
clinical (subjective) indicators of drug efficacy as compared to trials using objective (device-based) methods of drug effect
measurement.
Conclusions: The placebo effect is more prominent in treatment of asthma as compared to pharmacotherapy of arterial
hypertension. Its extent depends on the applied methods of drug efficacy measurement and is often greater if only clinical
indicators are used. This phenomenon can lead to different interpretations of treatment goals in asthma as perceived by the
physician and the patient. This also points out the necessity of patient activation in taking control over his/her disease so as
to achieve a better and more satisfying treatment result.
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Introduction
The efficacy of therapeutic interventions does
not only rely on their potential to modify the cour-
se of the disease, as best exemplified by pharmaco-
logical therapy, where the specific drug effect is not
the exclusive curative mechanism involved [13].
Contemporary treatment of asthma is aimed
at controlling the course of the disease using va-
rious inhaled agents having different mechanisms
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of action. These include mainly anti-inflammato-
ry drugs (glycocorticosteroids) and bronchodilators
(beta-agonists) [4]. Similarly to other chronic di-
seases, there is also a milieu effect of the invo-
lved in therapy of asthma. Referred to as the pla-
cebo effect, this phenomenon can at times be
strong enough to become a significant element of
the therapeutic process, apart from the well-defi-
ned actions of the applied antiasthmatic pharma-
cologic agents. The particularities of the placebo
effect may have some explanation in yet unknown
pathophysiological mechanisms of allergic reac-
tions underlying asthma, interactions between the
immune system and the nervous system (inclu-
ding the patients psyche) or the characteristics
of the disease, with its episodic appearance of
symptoms. This may lead to specific patient pre-
ferences as to the choice of particular agents.
Antiasthmatic drugs are tested and evaluated
during numerous pre- and postregistration trials,
where their effects are compared to placebo. Ho-
wever, there are no analyses concerning the propor-
tion of drug effect and placebo effect in the overall
treatment result in asthma.
The aim of the current study was to evaluate
the placebo effect in the treatment of asthma ba-
sed on the results of previously published high
quality trials concerning inhaled antiasthmatic
agents. Moreover, the extent of the placebo effect
in the therapy of asthma was also evaluated with
respect to various applied investigative methods.
Material and methods
Material
A systematic search of the Medline database
(using the Entrez Pubmed browser) was performed
in order to identify randomized placebo-control-
led (most often double-blinded) trials concerning
inhaled antiasthmatic drugs and (for comparison)
antihypertensive agents.
The following antiasthmatic agents were inc-
luded in the analysis:
a) beclomethasone, fluticasone,
b) formoterol.
The following antihypertensive agent was also
analysed for comparison:
c) captopril.
Search terms included: international drug
name in English (beclomethasone, fluticasone, for-
moterol, captopril) and the words: inhaled (for
antiasthmatic agents), randomised, placebo con-
trolled.
Table 1 presents the results of a literature se-
arch for particular pharmacologic agents as the first
step of the analysis. An initial verification proce-
dure was performed so as to exclude browser-rela-
ted errors. The trials included in the final analysis
fulfilled the following criteria:
a) trial concerned only asthma or only arterial
hypertension (for captopril);
b) results of trial were published in a peer-revie-
wed journal;
c) of all the patients who completed the trial, the
number of persons receiving an active phar-
macologic agent (study group) was similar to
the control group receiving placebo, with an
intergroup difference of not more than 5%;
d) inclusion criteria were clearly defined, and in-
dicators of treatment were efficacy well esta-
blished, including both the objectively measura-
ble effects (e.g. FEV1 or PEF as objective markers
of bronchial hyperreactivity) and subjective esti-
mators, including parameters assessed by patients
themselves of by investigators (various scales of
disease intensity, amount of drugs consumed, qu-
ality of life measurement). Study duration, end-
points, and final results had to be clearly presen-
ted and available in the publication main text or
abstract for further re-evaluation.
Statistical analysis
All statistical analyses were performed with
kind assistance from Prof. Mieczys‡aw K‡opotek Dr.
Ing. (Institute of Computer Sciences, Polish Aca-
demy of Sciences) and Maciej Michalewicz Dr. Ing.
Table 1. Stages of a systematic review of the studies eligible for analysis
 Agent Trials identified Trials after initial verification Qualified for analysis
n  n (%) n (%)
Beclomethasone 111 95 (86) 10 (11)
Fluticasone 210 170 (81) 29 (17)
Formoterol 133 110 (83) 2 (2)
Captopril 232 192 (83) 10 (5)
Total 686 567 (83) 51 (7)
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(IBM Poland). Three variables were analysed for
each trial, when possible:
a) effect of treatment reflecting changes in the
measured parameter in the study group (EL);
b) placebo effect reflecting changes in the measu-
red parameter in the placebo group (EP);
c) placebo effect to treatment effect ratio, reflec-
ting proportion of the final treatment effect that
can be contributed to placebo effect (UEPL).
For some studies, the first two variables co-
uld not be analysed. Analysis was feasible if:
a) changes in the measured parameter were of in-
cremental or decremental character, with
known or obvious maximal (or minimal) va-
lue or established reference range;
b) changes in the measured parameter were of in-
cremental or decremental character, and its
maximal (or minimal) value or reference ran-
ge could be predicted (hypothesized).
At times, the measured parameters and their
characters precluded calculation of the EP and LP
values but UEPL could still be calculated; the lat-
ter was then accepted as the final analysis result.
When measured parameters were expressed in
percentage values, analysis was based on arithme-
tic mean values of the percentage of patients in the
study group and in the control group using Berno-
ulli distribution, with the assumption that both
patient groups were equal in size. Significant cor-
relations were assigned when probability was of
more than 0.95 or less than 0.05.
For trial results expressed as numeric values,
differences in arithmetic mean values were tested
for statistical significance between the study gro-
up and the control group using Students t test,
with the assumption that both groups were equal
in size. For some parameters, mean values and
standard deviation were calculated:
a) based on analogical studies, if significance le-
vel was given, or
b) assuming that standard deviation value does
not exceed mean value, or
c) assuming that standard deviation value is
known to the investigator from other sources.
If standard deviation (SD) from the mean value
was not given, reversed t test was used to determine
SD based on the p-value from another literature re-
ference. When using Students t test, an adequate
number of degrees of freedom was assumed, taking
into account the number of patients in the study gro-
up and the control group. Corrected standard devia-
tion for a single trial was also estimated.
Various parameters are used in trials concer-
ning different diseases. These are, however, extre-
mely heterogeneous and difficult to summarize;
therefore, the study group was replaced by a me-
tapatient for the sake of metaanalysis, and respec-
tive parameters were replaced by the notions of EL
in relation to EP. Consistency of respective trial
results was verified, being the main selection cri-
terion for further analysis.
Calculations
Mean values for all the analysed parameters
(both clinical and objective ones) as well as EL, EP,
and UEPL for the four drugs in question were cal-
culated. The following drug combinations were
also investigated in the same manner:
a) beclomethasone and fluticasone;
b) beclomethasone, fluticasone, and formoterol.
Analogical calculations were also performed for:
a) trials using clinical parameters (through ob-
jectivisation of anamnestic data);
b) trials using objective parameters (using given
measurement results).
Next step involved comparison of mean values
for respective drugs, combinations of drugs (antia-
sthmatic agents and captopril) and for treatment of
asthma and hypertension (the latter therapy invo-
lving captopril). Calculation results were presented
graphically and in tables, giving mean values and p
values for differences between the analysed groups.
Results
Clinical efficacy of the studied drugs versus
efficacy of placebo
Cumulative results of calculations based on
subjective and objective parameter values for an-
tiasthmatic agents are presented in figure 1.
The two analysed inhaled glycocorticostero-
ids had different efficacy. Fluticasone caused im-
provement of 68%, and beclomethasone 49%, but
EP for fluticasone was almost 1.5 times better. The
effect of beclomethasone therapy was greater than
EP (2.9 times) and exceeded the effect of fluticaso-
ne (2.5 times the effect of placebo); the difference
was not statistically significant, though.
Formoterol had a weaker effect as compared
to other agents (17% EL). Placebo effect for this
drug was also weaker (4%). The effect of the drug
significantly exceeded its EP (by 4.9 times).
Captopril had a 44% EL, with low EP effect of
9% on average. The effect of the drug exceeded the
placebo effect by 5 times.
The greatest difference between EL and EP was
observed for captopril (5.0) and formoterol (4.9),
with a statistically significant difference (p >0.001)
between these agents and inhaled glycocorticoste-
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roids (with respective values of 2.9 for beclome-
thasone and 2.5 for fluticasone).
Cumulative EL of antiasthmatic drugs (beclo-
methasone, fluticasone, and formoterol) in the ci-
ted trials was 54%. Control groups receiving pla-
cebo had a significantly weaker effect of 23% (p
<0.001). Summaric EL effect of antiasthmatic
agents exceeded EP by 1.9 times, and thus was si-
gnificantly less than that of captopril (p < 0.001).
Comparison of different methods of treatment
effect measurement
Analysis concerning various methods of treat-
ment efficacy assessment revealed that the placebo
effect was significantly stronger (p < 0.001) when
clinical indicators of efficacy were employed (mean
effect of 59%) as compared to studies using objecti-
ve measurements (mean effect of 29%).
Contribution of drugs and placebo to the
overall treatment effect
Figure 2 depicts the contribution of respecti-
ve pharmacological agents and placebo to the ove-
rall treatment effect measured using both clinical
and objective indicators. The weakest placebo ef-
fect was observed in trials concerning captopril,
whereas among antiasthmatic agents the least ef-
fective was shown to be formoterol, followed by
beclomethasone and fluticasone.
Discussion
The presented analysis demonstrates that the
placebo effect plays an important role in the treat-
ment of asthma. This observation concerns all the
three analysed inhaled antiasthmatic agents, with
placebo effect greater than that of an antihyperten-
sive agent. The finding may imply that asthmatic
patients are more prone to placebo effect and bene-
fit from it to a larger extent than patients with hy-
pertension. The role of psychosomatic phenomena
in asthma can therefore be hypothesized, which
reflects a growing field of scientific interest [510].
The coincidence of asthma with anxiety and
depressive disorders is well known. Some authors
and doctrines suggest the necessity of addressing
these issues in order to improve results of asth-
ma therapy [4, 11]. The patients feeling of having
greater control of the disease and increased safe-
ty may decrease the intensity of asthmatic symp-
toms to a greater extent as compared to other ail-
ments. Current recommendations concerning the
treatment of asthma emphasise the necessity of
stress reduction in patients [4]. Greater patient
engagement in disease monitoring and decision-
making concerning administration of fast acting
medication is suggested.
The presented analysis demonstrates that
methods (objective versus subjective) and condi-
tions of therapeutic efficacy assessment are crucial
for evaluation of the placebo effect. Clinical para-
meters are more widely used in recent trials, gi-
ven their simplicity, low cost, non-invasive cha-
racter, and possibility of quick assessment, altho-
ugh subjective character and lack of accuracy are
still admitted in these settings. The current analy-
sis confirmed that the more subjective measure-
ment techniques applied in asthma treatment, the
less precise the results. These are, however, closer
Figure 1. Average EL and EP levels in placebo-controlled trials of efficacy of antiasthmatic inhaled drugs evaluated by objective and subjective indicators
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to the patients perception of the disease course and
treatment effect. The presented results also demon-
strate that the more subjective evaluation methods
applied, the greater the extent of the placebo ef-
fect in the cumulative result of treatment.
To assess if a given therapeutic intervention
(drug) has a real impact on a disease course, a stu-
dy group in a clinical trial is observed to find out
if these individuals experience a greater treatment
effect than subjects in a control group who receive
placebo. In the latter group, however, there is also
the influence of natural, non-drug-dependent ten-
dencies for convalescence. This approach is cor-
rect, given that the intervention (drug) is most often
developed based on rational knowledge of the di-
sease, and the question to be answered is whether
this intervention can have a beneficial effect on the
given disease. Efficacy of the intervention is the-
refore perceived as its effect on the already known
disease-causing mechanisms. Physicians intend to
use medication of known and proven efficacy but
they actually observe and measure the cumulati-
ve effect of treatment. This may mean that a bene-
ficial effect can be also obtained if other agents or
interventions, with no perceptible effect on the
disease, are applied. Many well-established drugs,
including antiasthmatic agents, undergo negative
verification with time. Comparing their therapeu-
tic effects with those of the placebo can prove that
interventions with no real influence on the dise-
ase course can be erroneously perceived as bene-
ficial [12-14]. The presented results show that such
errors can occur in daily practice, and physicians
are not able, even approximately, to estimate pro-
portional contributions of different interventions
to the overall therapeutic effect. In addition, phy-
sicians tend to underestimate the placebo effect,
which is a reason for the success of many alterna-
tive medical interventions and strategies.
The UEPL ratio adopted in this study is easy
to calculate using the available data and reflects
the proportions between a real therapeutic effect
of the drug and that of the placebo. Using it per-
mits clear definition of both proportions, which
can be useful in daily practice but also making
comparisons and analyses giving a greater insight
into the placebo effect.
It is well known that the disease and its treat-
ment have impact an on the patients perception
of his/her environment and effects of therapy but
can also influence the degree of the experienced
placebo effect, and asthma is a good example of
this. Numerous studies emphasise specific psychi-
cal features of affected patients, some of them of
almost borderline character, which may predispo-
se them to a greater benefit from the placebo ef-
fect. The presented study confirms these theories,
demonstrating that patients with asthma can expe-
rience a particularly strong placebo effect if treat-
ment outcomes are measured by clinical indicators
and scales. Of note, the placebo effect varied be-
tween different trials concerning the same drug,
which warrants greater attention to the interpreta-
tion of published results, even in cases of proper-
ly constructed and formally immaculate trials on
antiasthmatic drugs.
Figure 2. Average share of placebo in a total effect of treatment in in placebo-controlled trials of efficacy of antiasthmatic inhaled drugs
evaluated by objective and subjective indicators
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Conclusions
1. Contribution of the placebo effect in high-qu-
ality clinical trials on inhaled antiasthmatic
drugs was variegated but significantly greater
as compared to studies on an antihypertensi-
ve agent, captopril.
2. Greater placebo effect was observed in trials whe-
re the therapeutic effects were measured using
subjective (clinical) indicators as compared to
analyses based on more subjective assessments
(device-based readings and measurements).
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